• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NICOX SA

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
July 17, 2025
From NICOX SA
Via GlobeNewswire
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
June 30, 2025
From NICOX SA
Via GlobeNewswire
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan
May 27, 2025
From NICOX SA
Via GlobeNewswire
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
May 14, 2025
From NICOX SA
Via GlobeNewswire
Nicox Provides Full Year 2024 Financial Results
April 30, 2025
From NICOX SA
Via GlobeNewswire
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
March 19, 2025
From NICOX SA
Via GlobeNewswire
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
March 03, 2025
From NICOX SA
Via GlobeNewswire
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025
January 28, 2025
From NICOX SA
Via GlobeNewswire
Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights
January 21, 2025
From NICOX SA
Via GlobeNewswire
Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream
December 04, 2024
From NICOX SA
Via GlobeNewswire
Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected
December 02, 2024
From NICOX SA
Via GlobeNewswire
Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial
November 19, 2024
From NICOX SA
Via GlobeNewswire
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results
October 17, 2024
From NICOX SA
Via GlobeNewswire
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
September 23, 2024
From NICOX SA
Via GlobeNewswire
Nicox Announces Approval of ZERVIATE in China
September 18, 2024
From NICOX SA
Via GlobeNewswire
Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board
September 04, 2024
From NICOX SA
Via GlobeNewswire
Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470
July 25, 2024
From NICOX SA
Via GlobeNewswire
Nicox announces attendance at upcoming conferences
July 19, 2024
From NICOX SA
Via GlobeNewswire
Nicox Provides Second Quarter 2024 Update
July 18, 2024
From NICOX SA
Via GlobeNewswire
Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director
July 16, 2024
From NICOX SA
Via GlobeNewswire
Nicox: 2024 Ordinary Shareholder Meeting
June 27, 2024
From NICOX SA
Via GlobeNewswire
Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024
May 24, 2024
From NICOX SA
Via GlobeNewswire
Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024
May 06, 2024
From NICOX SA
Via GlobeNewswire
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent
April 24, 2024
From NICOX SA
Via GlobeNewswire
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
April 22, 2024
From NICOX SA
Via GlobeNewswire
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap